Literature DB >> 4362643

Lipid-protein interactions in high density lipoproteins.

G Assmann, H B Brewer.   

Abstract

Delipidated high density lipoprotein (apo-HDL), isolated apolipoproteins apoA-I and apoA-II, S-carboxymethylated apoA-II, apoC-III, the NH(2)- and COOH-terminal CNBr peptides of apoA-II, and the COOH-terminal CNBr peptide of apoA-I were recombined in vitro with [N-C(3)H(3)-choline]phosphatidylcholine (PC) and [N-(14)CH(3)-choline]sphingomyelin (SPM). The lipid-protein complexes were analyzed by ultracentrifugal flotation, agarose gel chromatography and circular dichroism. ApoHDL, apoA-II, and S-carboxymethylated apoA-II readily recombined with PC or SPM to form particles that were similar in size to native HDL. The COOH- but not the NH(2)-terminal CNBr peptide of apoA-II recombined with lipid. ApoA-I and the COOH-terminal CNBr peptide of apoA-I, however, recombined with PC or SPM to only a limited extent, suggesting that protein-protein interactions between apoA-I and apoA-II are important in the integration of apoA-I into recombined lipoprotein particles. Analysis of the recombined lipid-protein complexes by circular dichroism indicated that there was an increase in helical structure concomitant with lipid-protein binding. The reconstituted particles had many of the physical and chemical properties of the native lipoprotein.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4362643      PMCID: PMC388143          DOI: 10.1073/pnas.71.3.989

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Human high density lipoprotein, apolipoprotein glutamine II. The immunochemical and lipid-binding properties of apolipoprotein glutamine II derivatives.

Authors:  R L Jackson; J D Morrisett; H J Pownall; A M Gotto
Journal:  J Biol Chem       Date:  1973-08-10       Impact factor: 5.157

2.  Fractionation of the C-apoproteins from human plasma very low density lipoproteins.

Authors:  P N Herbert; R S Shulman; R I Levy; D S Fredrickson
Journal:  J Biol Chem       Date:  1973-07-25       Impact factor: 5.157

3.  Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion.

Authors:  Y H Chen; J T Yang; H M Martinez
Journal:  Biochemistry       Date:  1972-10-24       Impact factor: 3.162

4.  Isolation of a helical, lipid-binding fragment from the human plasma high density lipoprotein, apoLP GLN-I.

Authors:  R L Jackson; H N Baker; J S David; A M Gotto
Journal:  Biochem Biophys Res Commun       Date:  1972-12-18       Impact factor: 3.575

5.  Isolation and characterization of apoLp-Gln-II (apoA-II), a plasma high density apolipoprotein containing two identical polypeptide chains.

Authors:  S E Lux; K M John; H B Brewer
Journal:  J Biol Chem       Date:  1972-12-10       Impact factor: 5.157

6.  Structure of human serum lipoproteins.

Authors:  A M Scanu
Journal:  Ann N Y Acad Sci       Date:  1972-06-20       Impact factor: 5.691

7.  The influence of lipid on the conformation of human plasma high density apolipoproteins.

Authors:  S E Lux; R Hirz; R I Shrager; A M Gotto
Journal:  J Biol Chem       Date:  1972-04-25       Impact factor: 5.157

8.  Heterogeneity in protein subunits of human serum high-density lipoproteins.

Authors:  B Shore; V Shore
Journal:  Biochemistry       Date:  1968-08       Impact factor: 3.162

9.  Fractionation of human serum high density lipoprotein in urea solutions. Evidence for polypeptide heterogeneity.

Authors:  A Scanu; J Toth; C Edelstein; S Koga; E Stiller
Journal:  Biochemistry       Date:  1969-08       Impact factor: 3.162

10.  Forms of human serum high density lipoprotein protein.

Authors:  A Scanu
Journal:  J Lipid Res       Date:  1966-03       Impact factor: 5.922

View more
  18 in total

1.  The pathology of Tangier disease. A light and electron microscopic study.

Authors:  V J Ferrans; D S Fredrickson
Journal:  Am J Pathol       Date:  1975-01       Impact factor: 4.307

2.  Isolation and characterization of an abnormal high density lipoprotein in Tangier Diesase.

Authors:  G Assmann; P N Herbert; D S Fredrickson; T Forte
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

3.  Interaction of L-alpha-didecanoyl phosphatidylcholine with the AI polypeptide of high density lipoprotein.

Authors:  J A Reynolds; C Tanford; W L Stone
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

4.  Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.

Authors:  P Holvoet; S Danloy; E Deridder; M Lox; H Bernar; A Dhoest; D Collen
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

5.  [Tangier-disease (author's transl)].

Authors:  G Assmann
Journal:  Klin Wochenschr       Date:  1979-01-15

6.  A molecular model of high density lipoproteins.

Authors:  G Assmann; H B Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

7.  Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I.

Authors:  A von Eckardstein; H Funke; A Henke; K Altland; A Benninghoven; G Assmann
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 8.  [Lipid-protein-interactions of human apolipoproteins-structural aspects and models of lipoproteins (author's transl)].

Authors:  G Middelhoff; J Augustin; G Klose; H Greten
Journal:  Klin Wochenschr       Date:  1977-02-15

9.  High density lipoprotein metabolism in man.

Authors:  C B Blum; R I Levy; S Eisenberg; M Hall; R H Goebel; M Berman
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

10.  The effect of dietary n-3 polyunsaturated fatty acids on HDL cholesterol in Chukot residents vs muscovites.

Authors:  E Gerasimova; N Perova; I Ozerova; V Polessky; V Metelskaya; I Sherbakova; M Levachev; S Kulakova; Y u Nikitin; T Astakhova
Journal:  Lipids       Date:  1991-04       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.